Malady Kyle 4

What Happened

• Malady Kyle, a director of DexCom, was granted 5,575 restricted stock units (RSUs) on May 28, 2026. The Form 4 reports the acquisition price as $0.00 (total $0) because this is a compensation award rather than an open-market purchase or sale. Each RSU represents a contingent right to receive one share of DexCom common stock upon settlement.

Key Details

• Transaction date: May 28, 2026. Form 4 filed June 1, 2026 (accession 0001093557-26-000124).
• Transaction type/code: Award/Grant (A). Quantity: 5,575 RSUs. Reported price: $0.00; reported value: $0.
• Vesting (footnote F1): 100% of the RSU award vests on the earlier of the one‑year anniversary of the grant or DexCom’s 2027 Annual Meeting of Stockholders.
• Shares owned after transaction: Not disclosed in the filing.
• Tax withholding / settlement: No tax withholding or settlement details reported in this Form 4.
• Filing timeliness: The filing date is shown; the Form does not include a late‑filing flag in the provided data.

Context

• RSU grants are compensation, not market purchases or sales; eventual value depends on DexCom’s stock price when the RSUs settle. This award creates a contingent right to shares upon vesting and settlement rather than an immediate change in market‑held shares.